[go: up one dir, main page]

ECSP045234A - PROCEDIMIENTO PARA LA FABRICACION DE DERIVADOS DE ACIDO MEVALONICO INHIBIDORES DE ß-HIDROXI-ß-METILGLUTARILO-CO-ENZIMA-A REDUCTASA - Google Patents

PROCEDIMIENTO PARA LA FABRICACION DE DERIVADOS DE ACIDO MEVALONICO INHIBIDORES DE ß-HIDROXI-ß-METILGLUTARILO-CO-ENZIMA-A REDUCTASA

Info

Publication number
ECSP045234A
ECSP045234A EC2004005234A ECSP045234A ECSP045234A EC SP045234 A ECSP045234 A EC SP045234A EC 2004005234 A EC2004005234 A EC 2004005234A EC SP045234 A ECSP045234 A EC SP045234A EC SP045234 A ECSP045234 A EC SP045234A
Authority
EC
Ecuador
Prior art keywords
manufacture
glutarilo
enzima
reductasa
hidroxi
Prior art date
Application number
EC2004005234A
Other languages
English (en)
Inventor
Gottfried Sedelmeier
Christian Mathes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP045234A publication Critical patent/ECSP045234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/535—Organo-phosphoranes
    • C07F9/5352—Phosphoranes containing the structure P=C-
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0033—Iridium compounds
    • C07F15/004—Iridium compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0046—Ruthenium compounds
    • C07F15/0053—Ruthenium compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0073—Rhodium compounds
    • C07F15/008—Rhodium compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/04—Nickel compounds
    • C07F15/045—Nickel compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/06—Cobalt compounds
    • C07F15/065—Cobalt compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La invención se refiere a un procedimiento para la fabricación de un compuesto de la fórmula (I); o una sal, especialmente una sal farmacéuticamente aceptable con una base del mismo, o una lactona del mismo, en donde el elemento (a) representa -CH2-CH2- o -CH=CH, y R representa un radical cíclico.
EC2004005234A 2002-02-21 2004-08-16 PROCEDIMIENTO PARA LA FABRICACION DE DERIVADOS DE ACIDO MEVALONICO INHIBIDORES DE ß-HIDROXI-ß-METILGLUTARILO-CO-ENZIMA-A REDUCTASA ECSP045234A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0204129.1A GB0204129D0 (en) 2002-02-21 2002-02-21 Process for the manufacture of organic compounds

Publications (1)

Publication Number Publication Date
ECSP045234A true ECSP045234A (es) 2004-09-28

Family

ID=9931523

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005234A ECSP045234A (es) 2002-02-21 2004-08-16 PROCEDIMIENTO PARA LA FABRICACION DE DERIVADOS DE ACIDO MEVALONICO INHIBIDORES DE ß-HIDROXI-ß-METILGLUTARILO-CO-ENZIMA-A REDUCTASA

Country Status (18)

Country Link
US (3) US7208623B2 (es)
EP (1) EP1478640A1 (es)
JP (1) JP2005520818A (es)
KR (1) KR100978970B1 (es)
CN (1) CN1318412C (es)
AU (1) AU2003218994B2 (es)
BR (1) BR0307801A (es)
CA (1) CA2473075A1 (es)
EC (1) ECSP045234A (es)
GB (1) GB0204129D0 (es)
IL (1) IL163279A (es)
MX (1) MXPA04008110A (es)
NO (1) NO20043919L (es)
NZ (1) NZ534394A (es)
PL (1) PL370596A1 (es)
RU (1) RU2335500C2 (es)
WO (1) WO2003070717A1 (es)
ZA (1) ZA200405436B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds
CN101219992B (zh) 2003-02-12 2011-08-31 日产化学工业株式会社 匹伐他汀钙的晶形
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
EP1634870A1 (en) * 2004-08-27 2006-03-15 Zhejiang Hisun Pharmaceutical Co. Ltd. Process and intermediates for the selective synthesis of Fluvastatin
EP1817027A2 (en) * 2004-09-27 2007-08-15 Ranbaxy Laboratories Limited Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof
US8354530B2 (en) 2005-07-28 2013-01-15 Lek Pharmaceuticals d. d Process for the synthesis of rosuvastatin calcium
US8455640B2 (en) 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2008053334A2 (en) * 2006-10-31 2008-05-08 Aurobindo Pharma Limited An improved process for preparing rosuvastatin calcium
EP2125754B1 (en) * 2007-02-08 2012-04-11 Aurobindo Pharma Limited Process for preparation of rosuvastatin calcium
KR20090033183A (ko) * 2007-04-18 2009-04-01 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴 중간체 및 로수바스타틴의 제조 방법
US20090069563A1 (en) * 2007-07-12 2009-03-12 Valerie Niddam-Hildesheim Rosuvastatin intermediates and their preparation
KR101063146B1 (ko) * 2008-11-10 2011-09-07 미래파인켐 주식회사 피타바스타틴 중간체의 제조방법 및 이를 이용한 피타바스타틴 헤미 칼슘염의 제조방법
EP2387561A4 (en) 2009-01-19 2012-07-25 Msn Lab Ltd IMPROVED PROCESS FOR THE PREPARATION OF HIGH-PURITY (3R, 5S) -7-β-CYCLOPROPYL-4- (4-FLUOROPHENYL) QUINOLIN-3-YL-3,5-DIHYDROXY-6 (E) -HEPTENOIC ACID, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS
EP2526099B1 (en) 2010-01-18 2016-03-30 MSN Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
EP2638013A4 (en) * 2010-11-12 2014-03-26 Hetero Research Foundation NEW POLYMORPHS OF CALCIUM PIVASTATIN
FR2970178B1 (fr) 2011-01-07 2014-06-20 Liliane Therese Jacquot Promedicaments pour une delivrance specifique au niveau du foie et une meilleure tolerance
CN103058925B (zh) * 2011-11-02 2015-09-02 石药集团中奇制药技术（石家庄）有限公司 一种匹伐他汀钙的制备方法
TWI516520B (zh) 2014-10-31 2016-01-11 財團法人工業技術研究院 波長轉換聚合物、其製法及包含其之波長轉換裝置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851427A (en) 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DK0577040T3 (da) 1992-07-02 1998-02-02 Hoechst Ag Fremgangsmåde til fremstilling af (3R,5S)6-hydroxy-3,,5-O-isopropyliden-3,5-dihydroxyhexansyre-tert.-butylester
US5763688A (en) 1994-12-07 1998-06-09 Research Development Corporation Of Japan Method for producing an alcohol
EP0916637B1 (en) 1995-12-06 2005-04-20 Japan Science and Technology Agency Process for preparating optically active compounds
JP3159661B2 (ja) * 1997-02-21 2001-04-23 科学技術振興事業団 光学活性アルコール類の製造方法
US6187961B1 (en) * 1997-11-06 2001-02-13 Roche Vitamins Inc. Process for the preparation of trans-(R,R)-actinol
JPH11322649A (ja) * 1998-03-16 1999-11-24 Mitsubishi Chemical Corp 光学活性アルコールの製造方法
JPH11335385A (ja) * 1998-05-20 1999-12-07 Takasago Internatl Corp 遷移金属錯体および該錯体を用いた光学活性アルコールの製造方法
JP2000212110A (ja) * 1999-01-27 2000-08-02 Mitsubishi Chemicals Corp 光学活性α―アルキルベンジルアルコ―ル類の製造方法
JP3630002B2 (ja) * 1999-03-03 2005-03-16 三菱化学株式会社 光学活性１，２−ジオール類の製造方法
JP2000327659A (ja) * 1999-03-15 2000-11-28 Mitsubishi Chemicals Corp 光学活性ピリジルアルコール類の製造方法
US6211412B1 (en) * 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
US6603015B2 (en) * 1999-03-29 2003-08-05 University Of Kansas Synthesis of epothilones
JP2001104795A (ja) * 1999-10-13 2001-04-17 Mitsubishi Chemicals Corp ルテニウム触媒組成物
JP3720235B2 (ja) * 2000-03-14 2005-11-24 高砂香料工業株式会社 光学活性ルテニウムホスフィン錯体の製造方法及び該錯体を用いた光学活性アルコールの製造方法
DK1136475T3 (da) * 2000-03-22 2004-12-27 Hoffmann La Roche Piperidin- og piperazinderivater til anvendelse i behandlingen af Alzheimer
AU2001274049A1 (en) * 2000-05-26 2001-12-11 Ciba Specialty Chemicals Holding Inc. Process for the preparation of indole derivatives and intermediates of the process
WO2002008169A1 (en) * 2000-07-24 2002-01-31 Chirotech Technology Limited Ruthenium complexes and their use in asymmetric hydrogenation
GB0204129D0 (en) 2002-02-21 2002-04-10 Novartis Ag Process for the manufacture of organic compounds

Also Published As

Publication number Publication date
US7208623B2 (en) 2007-04-24
GB0204129D0 (en) 2002-04-10
CN1636004A (zh) 2005-07-06
KR20040111360A (ko) 2004-12-31
ZA200405436B (en) 2005-06-17
PL370596A1 (en) 2005-05-30
AU2003218994B2 (en) 2007-08-09
US20050159480A1 (en) 2005-07-21
BR0307801A (pt) 2004-12-21
MXPA04008110A (es) 2004-11-26
AU2003218994A1 (en) 2003-09-09
CN1318412C (zh) 2007-05-30
CA2473075A1 (en) 2003-08-23
US20080312462A1 (en) 2008-12-18
RU2335500C2 (ru) 2008-10-10
US20070155970A1 (en) 2007-07-05
KR100978970B1 (ko) 2010-08-30
JP2005520818A (ja) 2005-07-14
NO20043919L (no) 2004-09-20
RU2004128256A (ru) 2005-06-27
IL163279A (en) 2010-06-30
NZ534394A (en) 2006-10-27
WO2003070717A1 (en) 2003-08-28
EP1478640A1 (en) 2004-11-24

Similar Documents

Publication Publication Date Title
ECSP045234A (es) PROCEDIMIENTO PARA LA FABRICACION DE DERIVADOS DE ACIDO MEVALONICO INHIBIDORES DE ß-HIDROXI-ß-METILGLUTARILO-CO-ENZIMA-A REDUCTASA
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
NO20060870L (no) Fluorsubstituert omega-karboksyaryldifenylurea for behandling og profylakse av sykdommer og tilstander
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
DE60225671D1 (de) Pharmazeutisch wirksame piperidinderivate
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
UA96565C2 (ru) Пиридильные ингибиторы хеджхоговской передачи сигнала
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
DK1613304T3 (da) DPP-IV-inhibitorer
NO20064077L (no) Kemokinreseptorantagonister
AR066972A1 (es) Derivados azapeptidicos
SE0400284D0 (sv) Novel compounds
EA200600621A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
AR050518A1 (es) Proceso de amonolisis para la preparacion de intermedarios para inhibidores de dpp iv
NO20065719L (no) I det vesentlige rene 2-{[2-(2-metylamino-pyrimidin-4-yl)-1H-indol-5-karbonyl]-amlno}-3-(fenylpyridin-2-yl-amino)-propionsyre som en IkB kinaseinhibitor.
DE602005016297D1 (de) Antithrombotische diamide
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
DK1670778T3 (da) Omlejrede pentanoler, en fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelsehæmmende
UY27577A1 (es) Inhibidores de la integrasa del vih
ATE441630T1 (de) Substituierte cyclopenten-verbindungen
ATE553077T1 (de) Peptidaseinhibitoren
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS